Drug Discovery World

FEBRUARY 20, 2024

billion in 2028 at a compound annual growth rate (CAGR) of 12.6%, according to analysts ResearchAndMarkets.com. Drug discovery informatics trends The increasing prevalence of chronic diseases is anticipated to play a large part in driving the expansion of the informatics market. million, including diabetes-induced kidney disease).

Marketing 130

Marketing Biosimilars Drugs Science 130

DrugBank

SEPTEMBER 26, 2024

Biosimilars  Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.

Biosimilars 69

Biosimilars Clinical Trials FDA Production 69

DrugBank

AUGUST 9, 2024

Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  Shorter exclusivity periods, driven by patent challenges and the introduction of generic or biosimilar competitors, significantly contribute to declining ROI.

Pharmaceuticals 76

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 76

FDA Law Blog: Biosimilars

OCTOBER 6, 2023

The amended regulation would read as follows (revisions underlined): In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae.

Laboratories 64

Laboratories FDA Regulations Compliance 64